A Response to: Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”
Year: 2022
Type: letter
Abstract: Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab'', which applied a composite definition of clinical remission in severe asthma, adapted from two Delphi studies [1, 2], to a pooled population of patients from the SIROCCO [3], CALIMA [4], and ZONDA [5] trials [6].We appreciate that including the ''no oral corticosteroid (OCS)'' use criterion for the SIR-OCCO and CALIMA trials in our analysis could cause confusion.The protocols for the SIR-OCCO and CALIMA clinical trials did not allow for reductions in maintenance OCS use during treatment and, as such, patients could not have achieved zero OCS use over the course of those two trials [3,4].Although our post hoc analysis did exclude SIROCCO and CALIMA patients who were using OCS at the baseline visit, we did not exclude patients who used OCS, allowed at the investigators discretion, during the trial; indeed, there were a small number of patients who used OCS during those trials and that is why ''no OCS'' was included as one of the four A.
Source: Advances in Therapy
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,190
Funder: AstraZeneca
OpenAlex ID: W4283315890
